TJ Bio

TJ Bio is a South Korean biotechnology company specializing in the development of ophthalmic therapeutics, including biosimilars and novel biologics. Established as a specialized R&D entity by Taejoon Pharmaceutical, the company leverages expertise in protein engineering to address high-demand treatments for retinal diseases. Its lead programs include biosimilars for blockbuster drugs like Lucentis and Eylea, which are currently in advanced clinical stages. TJ Bio aims to provide cost-effective and high-quality treatment options for patients suffering from age-related macular degeneration and other vascular eye disorders. The company is also exploring novel therapeutic candidates to expand its pipeline beyond biosimilars. By focusing on ophthalmology, TJ Bio seeks to strengthen its parent company's leadership in the eye care market.